Dott.ssa Ilaria Cetta, neurologa
In questa pagina del sito di Polimedica trovi le principali informazioni sulla dottoressa: formazione, esperienza professionale, prestazioni erogate e tempi di attesa per un consulto specialistico neurologico.
Nel caso in cui il tuo medico di famiglia ti abbia prescritto una visita neurologica, probabilmente sei nella pagina giusta e potresti prendere in considerazione di prenotare una visita con la dottoressa Cetta.
Con una carriera dedicata alla diagnosi e cura delle cefalee e delle malattie infiammatorie del sistema nervoso, la Dr.ssa Ilaria Cetta si distingue per la sua competenza clinica e impegno nella ricerca, maturata presso l’ospedale San Raffaele di Milano e perfezionata attraverso un percorso di studio con importanti esperienze anche all’estero (Parigi, Seul, Praga, Vienna) oltre che in altre Università ed ospedali italiani.
Presso il nostro Poliambulatorio si rivolgono pazienti provenienti da tutta la Basilicata e dalle regioni limitrofe che sono alla ricerca di trattamenti altamente specializzati e all’avanguardia, beneficiando di un’organizzazione frutto di oltre 30 anni di esperienza a servizio delle persone.
Modalità di prenotazione:
Tempi di attesa: da 15 a 30 giorni
(tempi d’attesa orientativi, in fase di prenotazione potrebbero essere anche inferiori o leggermente maggiori)
Presentazione
Specialista in neurologia
La dottoressa Cetta, è un medico neurologo, esperta nella diagnosi e cura delle cefalee.
Svolge la propria attività professionale presso l’Ospedale San Raffaele di Milano, dove segue pazienti ricoverati presso l’Unità Operativa di Neurologia principalmente per malattie infiammatorie quali la sclerosi multipla e cefalee primarie e secondarie, incluse l’ipotensione liquorale, ipertensione intracranica, emorragie cerebrali, dolori facciali atipici e la detossificazione per cefalea da abuso farmacologico.
L’attività ambulatoriale svolta presso la Polimedica di Melfi riguarda principalmente la diagnosi e il trattamento di:
- emicrania con e senz’aura;
- cefalea a grappolo;
- cefalea muscolo-tensiva;
- dolori facciali atipici;
- nevralgia trigeminale;
- trattamento con tossina botulinica per prevenzione emicrania;
- infiltrazione nel nervo occipitale e terapia con anticorpi monoclonali per la prevenzione emicranica;
Formazione e note curriculari
- PhD Student – Curriculum: Neuroscience and Experimental Neurology, Vita-Salute San Raffaele University, Milan
- Post-graduated training in Neurology at Vita-Salute San Raffaele University, Milan
- Member of the International Headache Society (IHS) as Junior Member Member of Resident and Research Fellow Section of European Academy of Neurology – RRFS-EAN Membership
- Participant: Advanced training seminar on headache disorders (ASC) San Raffaele Rome University, 21-23th March 2024
- Certified with Botulinum Toxin and Movement Disorders: Evaluation and Treatment practical course IRCCS San Raffaele Hospital (Milan)
- Certified with Migraine Headache Management 2023: Advancing Everyday Practice, Prague (Czech Republic)
- Certified with International Headache Accademy (iHEAD) of International Headache Society (IHS)
- 8th IHS International Headache Academy (iHEAD), Seoul, South Korea
- Certified with School of Advanced Studies – European Headache Federation at University of Rome La Sapienza, Rome 15th SAS – EHF
- Certified with Master in “Diagnosis and treatment of headaches” at University Campus Biomedico of Rome (UCBM), ASC, Rome
- Participant: Spring School of European Academy of Neurology Vien (Austria)
- Qualification to practice Medicine at University of Rome “La Sapienza”, Rome
- Clinical fellow-ship at Neurology Department, University of Paris XI – Kremlin-Bicetre Hospital University of Paris XI, Kremlin-Bicetre Hospital, Paris (France)
- Medical School Degree: 110/110 cum laude at University of Rome “La Sapienza”, Rome
Esperienza professionale
- PhD Student – Curriculum: Neuroscience and Experimental Neurology, Vita-Salute San Raffaele University, Milano
- Neurologist, Neurology Unit and Headache and Atypical Facial Pain Center, San Raffaele Hospital. Activities and responsibilities: clinical and research activities, sub-investigator in RCTs Field of interest: Headache, Migraine, Neuroimaging, Multiple Sclerosis and CNS Inflammatory Diseases.
- Research fellow at the Neuroimaging Research Unit (Director Professor M. Filippi), INSPE Division of Neuroscience, San Raffaele Scientific Institute, VitaSalute San Raffaele University, Milano
- Headache center and atypical facial pain, San Raffaele Hospital, Milan (Italy) – Outpatients ambulatory (diagnosis and treatment of primary headaches, monoclonal antibodies for migraine prevention, onabotulinum toxin A for chronic migraine, block of GON) and research activity; Participation to several randomized clinical trials as sub-investigator in the field of headache, migraine and neuroimaging.
- Sub-internship at Neurology Department, Policlinico Umberto I, University of Rome “La Sapienza”, Rome
- Clinical fellowship at Neurology Department and Internal Medicine, University of Paris XI – Kremlin-Bicetre Hospital, Paris (France)
Ulteriori note curriculari e pubblicazioni
- Baione V, Belvisi D, Cortese A, Cetta I, Tartaglia M, Millefiorini E, Berardelli A, Conte A. Cortical M1 plasticity and metaplasticity in patients with multiple sclerosis. Mult Scler Relat Disord. 2020 Feb;38:101494. doi: 10.1016/j.msard.2019.101494. Epub 2019 Nov 5. PMID: 31715502.
- Colombo B, Cetta I, Messina R, Filippi M. Stress in paediatric migraine: a trigger factor? Neurol Sci. 2020 Dec;41(Suppl 2):447-449. doi: 10.1007/s10072-020-04654-5. PMID: 32845480.
- Giordano A, Cetta I, Orrico M, Montini F, Sangalli F, Colombo B, Filippi M, Martinelli V. Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report. Neurol Sci. 2021 Oct;42(10):3969-3971. doi: 10.1007/s10072-021-05442-5. Epub 2021 Jul 23.PMID: 34297265; PMCID: PMC8299174.
- Cetta I,Messina R, Colombo B, Filippi M. Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report. J Neurol. 2022 Apr 14. doi: 10.1007/s00415-022-11128-5. Epub ahead of print. PMID: 35420352.
- Barbanti P, Egeo G, Aurilia C, d’Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, FilippiBonassi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F; FRIEND-Study Group. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 2022 Apr 9;23(1):46. doi: 10.1186/s10194-022-01396-x. PMID: 35397503.
- CettaI, Messina R, Zanandrea L, Colombo B, Filippi M. Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study. Neurol Sci. 2022 Jun 4. doi: 10.1007/s10072-022-06190-w. Epub ahead of print. PMID: 35662382.
- Messina R, Cetta I,Colombo B, Filippi M. Tracking the evolution of non-headache symptoms through the migraine attack. J Headache Pain. 2022 Nov 23;23(1):149. doi: 10.1186/s10194-022-01525-6. PMID: 36418943; PMCID:PMC9686019.
- Guerrieri S, Bucca C, Nozzolillo A, Genchi A, Zanetta C, Cetta I, Rugarli G, Gattuso I, Azzimonti M, Rocca MA, Moiola L, Filippi M; SanRaf MS Study Group. Ocrelizumab extended interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience. Eur J Neurol. 2023 May 25. doi:10.1111/ene.15891. Epub ahead of print. PMID:37227923.
- Messina R, Christensen RH, Cetta I, Ashina M, Filippi M. Imaging the brain and vascular reactions to headache treatments: a systematic review. J Headache Pain. 2023 May 24;24(1):58. doi: 10.1186/s10194-023-01590-5. PMID: 37221469; PMCID: PMC10207747.
- Vernieri F, Brunelli N, Guerzoni S, Iannone LF, Baraldi C, Rao R, Schiano di Cola F, Ornello R, Cevoli S, Lovati C, Albanese M, Perrotta A, Cetta I, Rossi SS, Taranta V, Filippi M, Geppetti P, Sacco S, Altamura C. Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study. J Neurol. 2023 Jul 19. doi: 10.1007/s00415-023-11872-2. Epub ahead of print. PMID: 37468621.
- Filippi M, Messina R, Bartezaghi M, Cetta I, Colombo B, Grazzi L, Martinelli D, Ornello R, Pichiecchio A, Raimondi D,Russo A, Sacco S, Splendiani A, Tassorelli C, Turrini R, ValsasinaP, Rocca MA; RESET BRAIN Study Group. The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN). J Neurol. 2023 Aug 8. doi: 10.1007/s00415-023-11879-9. Epub ahead of print. PMID: 37550498.
- Barbanti P, Aurilia C, Egeo G, Proietti S, D’Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S,Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I,Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A,Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S; ERT; for the Italian Migraine Registry study group. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter,prospective, observational study. J Neurol. 2024 Jan 17. doi: 10.1007/s00415-023-12103-4. Epub ahead of print. PMID: 38231271.
- Waliszewska-Prosół M, Montisano DA, Antolak M, Bighiani F, Cammarota F, Cetta I,Corrado M, Ihara K, Kartamysheva R, Petrušić I, Pocora MM, Takizawa T, Vaghi G, Martelletti P, Corso B, Raggi A; European Headache Federation School of Advanced Studies (EHF-SAS). The impact of primary headaches on disability outcomes: a literature reviewand meta-analysis to inform future iterations of the Global Burden of Disease study. J Headache Pain. 2024 Mar 4;25(1):27. doi: 10.1186/s10194-024-01735-0. PMID: 38433202; PMCID: PMC10910736.
Partecipazione a congressi:
- European Academy of Neurology – EAN 2020: Treatment Response To Erenumab In Refractory Migraine Patients – R. Messina, I. Cetta, S. Guerrieri, B. Colombo, M. Filippi,
- Associazione Neurologica Italiana per la ricercar sulle cefalee – ANIRCEF 2020: Tracking the evolution of non-headache symptoms through the migraine attack – R. Messina, I. Cetta, B. Colombo, M. Filippi
- Oral presentation at Migraine Trust Virtual Symposium – MTIS 2020
- Tracking The Evolution Of Non-Headache Symptoms Through The Migraine Attack; Roberta Messina, Ilaria Cetta, Bruno Colombo, Massimo Filippi
- Poster – Società Italiana di Neurologia – SIN 2020 Acute myocardial infarction in a patient with chronic migraine and triptan overuse treated with erenumab for migraine prevention: A case report ;I. Cetta, R. Messina, B. Colmbo, M. Filippi
- Oral presentation – World Congress of Neurology – WCN2021 & SIN2021
- TRACKING THE EVOLUTION OF NON-HEADACHE SYMPTOMS THROUGH THE MIGRAINE ATTACK; I. Cetta, R. Messina, B. Colombo, S. Tronci, M. Filippi
- Poster – American Accademy of Neurology – AAN 2021 Tracking the Evolution of Non-Headache Symptoms Through the Migraine Attack; R. Messina, I. Cetta, B. Colombo, M. Filippi
- Oral Presentation – Onabotulinum Toxin A as a bridge therapy from pills to mAbs – IRCCS Istituto Neurologico C. Besta – November 29th 2021 CLINICAL EXPERIENCES FROM REAL LIFE; I. Cetta, C. Butera, B. Colombo, R. Messina, R. Romeo, L. Zanandrea
- Poster – Retreat 2022 (March 2022, Baveno Italy) Tracking the evolution of non-headache symptoms through the migraine attack;I. Cetta, R. Messina, B. Colombo, M. Filippi
- ePresentation – European Academy of Neurology – EAN 2022 (Vien)
- COMPARISON OF EFFICACY AND SAFETY OF ANTI-CGRP ANTIBODIES BETWEEN OVER AND UNDER 65-YEAR-OLD MIGRAINE PATIENTS; I. Cetta, R. Messina, L. Zanandrea, B. Colombo, M. Filippi
- Poster at Migraine Trust International Symposium (MTIS), London, 8-11 Sept 2022; Comparison of efficacy and safety of anti-CGRP antibodies between over and under 65-year-old migraine patients; Cetta I, Messina R, Zanandrea L, Guerrieri S, Colombo B and Filippi M.
- Oral Presentation at Associazione Neurologica Italiana per la Ricerca sulle cefalee (ANIRCEF), Rome, 22-24 September 2022, Comparison of efficacy and safety of anti-CGRP antibodies between over and under 65-year-old migraine patients; Cetta I, Messina R, Zanandrea L, Colombo B and Filippi M.
Faculty and speaker activities
- Approccio al paziente con cefalea: dalla clinica all’imaging – Milan, 9th Jun 2021
- Le terapie ad hoc per il paziente emicranico – Milan, 15th Sept 2021
- Onabotulinum Toxin A as a bridge therapy from pills to mAbs – IRCCS Istituto Neurologico C. Besta
- November 29th 2021
- Advanced Campus in Migraine: Dalla comprensione della fisiopatologia emicranica e alla definizione dei percorsi diagnostico-terapeutici – IRCCS San Raffaele Hospital, Milan 3-4th Nov 2022
- Corso di alta formazione in terapie avanzate delle cefalee: terapie farmacologiche e psicofarmacologiche (ASC) – Università San Raffaele Roma, 23-25th Mar 2023
- Empossible, the new era: evolvere per trasformare la gestione dell’emicrania – Rome, 26-27th May 2023
- Corso di Alta Formazione in tema di Cefalee – IRCCS San Raffaele Hospital, Milan 2-3 November 2023
- Corso di alta formazione in terapie avanzate delle cefalee – Advanced training
Novità e articoli da Polimedica
Ad ottobre l’ecografia al seno la dona Polimedica
Tumore al seno: precisione diagnostica elevatissima col nuovo mammografo
UniSalute è un nuovo partner di Polimedica
Contatta la dottoressa Cetta
La comunicazione verrà recapitata alla segreteria che la inoltrerà alla dottoressa Cetta